Gilead’s remdesivir prevents Covid-19 progression in preclinical study
Excerpt from the article:
A preclinical study in the US found that Gilead Sciences’ antiviral drug candidate remdesivir prevented disease progression in rhesus macaques monkeys with Covid-19.
“The animals were infected with the novel coronavirus, SARS-CoV-2.
Data announced by the National Institutes of Health (NIH) revealed a significant decrease in clinical disease and reduced lung damage in monkeys treated with the investigational antiviral drug.”
Click the button below to read the article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?